메뉴 건너뛰기




Volumn 18, Issue 3, 2013, Pages 314-322

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

(19)  Lacouture, Mario E a   Duvic, Madeleine b   Hauschild, Axel c   Prieto, Victor G d   Robert, Caroline e   Schadendorf, Dirk f   Kim, Caroline C g   McCormack, Christopher J h   Myskowski, Patricia L a   Spleiss, Olivia i   Trunzer, Kerstin i   Su, Fei j   Nelson, Betty k   Nolop, Keith B l   Grippo, Joseph F j   Lee, Richard J j   Klimek, Matthew J j   Troy, James L m   Joe, Andrew K j  


Author keywords

Cuscc; Dermatologic; Keratoacanthoma; Vemurafenib

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIHISTAMINIC AGENT; B RAF KINASE; DACARBAZINE; KERATOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PREDNISOLONE; RAF PROTEIN; STEROID; VEMURAFENIB;

EID: 84875453915     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0333     Document Type: Article
Times cited : (175)

References (35)
  • 1
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 2
    • 0036894746 scopus 로고    scopus 로고
    • BRAF and RAS mutations in human lung cancer and melanoma
    • Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
    • (2002) Cancer Res , vol.62 , pp. 6997-7000
    • Brose, M.S.1    Volpe, P.2    Feldman, M.3
  • 3
    • 10744222648 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in benign and malignant melanocytic lesions
    • Yazdi AS, Palmedo G, Flaig MJ et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-1162.
    • (2003) J Invest Dermatol , vol.121 , pp. 1160-1162
    • Yazdi, A.S.1    Palmedo, G.2    Flaig, M.J.3
  • 4
    • 79960027865 scopus 로고    scopus 로고
    • BRAF targeted therapy changes the treatment paradigm in melanoma
    • Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8:426-433.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 426-433
    • Ribas, A.1    Flaherty, K.T.2
  • 5
    • 33847220364 scopus 로고    scopus 로고
    • Melanoma biology and new targeted therapy
    • Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
    • (2007) Nature , vol.445 , pp. 851-857
    • Gray-Schopfer, V.1    Wellbrock, C.2    Marais, R.3
  • 6
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 7
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 8
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 10
    • 33749018219 scopus 로고    scopus 로고
    • Mechanisms of cutaneous toxicities to EGFR inhibitors
    • Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6: 803-812.
    • (2006) Nat Rev Cancer , vol.6 , pp. 803-812
    • Lacouture, M.E.1
  • 11
    • 56449119043 scopus 로고    scopus 로고
    • Keratosis pilaris: A follicular hyperkeratosis
    • Hwang S, Schwartz RA. Keratosis pilaris: A follicular hyperkeratosis. Cutis 2008;82: 177-180.
    • (2008) Cutis , vol.82 , pp. 177-180
    • Hwang, S.1    Schwartz, R.A.2
  • 12
    • 84856582443 scopus 로고    scopus 로고
    • Ultraviolet A and photosensitivity during vemurafenib therap
    • Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366:480-481.
    • (2012) N Engl J Me , vol.366 , pp. 480-481
    • Dummer, R.1    Rinderknecht, J.2    Goldinger, S.M.3
  • 13
    • 80054044954 scopus 로고    scopus 로고
    • Vemurafenib in melanoma with BRAF V600E mutation
    • Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365:1448-1449.
    • (2011) N Engl J Med , vol.365 , pp. 1448-1449
    • Dalle, S.1    Poulalhon, N.2    Thomas, L.3
  • 14
    • 84858729203 scopus 로고    scopus 로고
    • Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management
    • Zimmer L, Livingstone E, Hillen U et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012;148:357-361.
    • (2012) Arch Dermatol , vol.148 , pp. 357-361
    • Zimmer, L.1    Livingstone, E.2    Hillen, U.3
  • 15
    • 84863463901 scopus 로고    scopus 로고
    • Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition
    • Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012;30: 2375-2383.
    • (2012) J Clin Oncol , vol.30 , pp. 2375-2383
    • Zimmer, L.1    Hillen, U.2    Livingstone, E.3
  • 17
    • 41149092411 scopus 로고    scopus 로고
    • Keratoacanthoma and infundibulocystic squamous cell carcinoma
    • Kossard S, Tan KB, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008;30:127-134.
    • (2008) Am J Dermatopathol , vol.30 , pp. 127-134
    • Kossard, S.1    Tan, K.B.2    Choy, C.3
  • 18
    • 77953590523 scopus 로고    scopus 로고
    • Keratoacanthoma: Facts and controversies
    • Ko CJ. Keratoacanthoma: Facts and controversies. Clin Dermatol 2010;28:254-261.
    • (2010) Clin Dermatol , vol.28 , pp. 254-261
    • Ko, C.J.1
  • 19
    • 33845705260 scopus 로고    scopus 로고
    • Keratoacanthomas associated with sorafenib therapy
    • Kong HH, Cowen EW, Azad NS et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-172.
    • (2007) J Am Acad Dermatol , vol.56 , pp. 171-172
    • Kong, H.H.1    Cowen, E.W.2    Azad, N.S.3
  • 20
    • 68949094219 scopus 로고    scopus 로고
    • Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib
    • Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27: e59-e61.
    • (2009) J Clin Oncol , vol.27
    • Arnault, J.P.1    Wechsler, J.2    Escudier, B.3
  • 21
    • 65249127575 scopus 로고    scopus 로고
    • Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib
    • Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-23.
    • (2009) Clin Genitourin Cancer , vol.7 , pp. 20-23
    • Dubauskas, Z.1    Kunishige, J.2    Prieto, V.G.3
  • 22
    • 84855435059 scopus 로고    scopus 로고
    • Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    • Arnault JP, Mateus C, Escudier B et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18: 263-272.
    • (2012) Clin Cancer Res , vol.18 , pp. 263-272
    • Arnault, J.P.1    Mateus, C.2    Escudier, B.3
  • 23
    • 77957350123 scopus 로고    scopus 로고
    • Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
    • Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(suppl 15):8503.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15 , pp. 8503
    • Kefford, R.1    Arkenau, H.2    Brown, M.P.3
  • 25
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 26
    • 79951498422 scopus 로고    scopus 로고
    • PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial
    • Lacouture ME, McArthur GA, Chapman PB et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28(suppl 15):8592.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15 , pp. 8592
    • Lacouture, M.E.1    McArthur, G.A.2    Chapman, P.B.3
  • 27
    • 0024413216 scopus 로고
    • Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation?
    • Corominas M, Kamino H, Leon J et al. Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A 1989;86:6372-6376.
    • (1989) Proc Natl Acad Sci U S A , vol.86 , pp. 6372-6376
    • Corominas, M.1    Kamino, H.2    Leon, J.3
  • 28
    • 84862908526 scopus 로고    scopus 로고
    • RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
    • Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-321.
    • (2012) J Clin Oncol , vol.30 , pp. 316-321
    • Oberholzer, P.A.1    Kee, D.2    Dziunycz, P.3
  • 29
    • 84862908097 scopus 로고    scopus 로고
    • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    • Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215.
    • (2012) N Engl J Med , vol.366 , pp. 207-215
    • Su, F.1    Viros, A.2    Milagre, C.3
  • 30
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-430.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3
  • 31
    • 68949097283 scopus 로고    scopus 로고
    • Viral-associated nonmelanoma skin cancers: A review
    • Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: A review. Am J Dermatopathol 2009;31:561-573.
    • (2009) Am J Dermatopathol , vol.31 , pp. 561-573
    • Dubina, M.1    Goldenberg, G.2
  • 32
    • 84868193136 scopus 로고    scopus 로고
    • Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
    • Anforth RM, Blumetti TC, Kefford RF et al. Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167: 1153-1160.
    • (2012) Br J Dermatol , vol.167 , pp. 1153-1160
    • Anforth, R.M.1    Blumetti, T.C.2    Kefford, R.F.3
  • 33
    • 84863376176 scopus 로고    scopus 로고
    • Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma
    • Alloo A, Garibyan L, LeBoeuf N et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012;148: 363-366.
    • (2012) Arch Dermatol , vol.148 , pp. 363-366
    • Alloo, A.1    Garibyan, L.2    Leboeuf, N.3
  • 34
    • 84864021610 scopus 로고    scopus 로고
    • Systemic retanoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib
    • Anforth R, Bluemetti TC, Mohd Affandi A et al. Systemic retanoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012;30: e165-e167.
    • (2012) J Clin Oncol , vol.30
    • Anforth, R.1    Bluemetti, T.C.2    Mohd Affandi, A.3
  • 35
    • 84872679025 scopus 로고    scopus 로고
    • Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
    • Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025-1039.
    • (2012) J Am Acad Dermatol , vol.67 , pp. 1025-1039
    • Chen, A.P.1    Setser, A.2    Anadkat, M.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.